Agenus (AGEN) Competitors $3.66 -0.18 (-4.69%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$3.68 +0.02 (+0.55%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. XOMA, LXRX, VNDA, CDXS, SGMO, IRWD, ACHV, DOMH, FBIO, and CRISShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Achieve Life Sciences (ACHV), Dominari (DOMH), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Agenus vs. XOMA Lexicon Pharmaceuticals Vanda Pharmaceuticals Codexis Sangamo Therapeutics Ironwood Pharmaceuticals Achieve Life Sciences Dominari Fortress Biotech Curis Agenus (NASDAQ:AGEN) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Does the media favor AGEN or XOMA? In the previous week, Agenus had 6 more articles in the media than XOMA. MarketBeat recorded 19 mentions for Agenus and 13 mentions for XOMA. XOMA's average media sentiment score of 0.81 beat Agenus' score of 0.76 indicating that XOMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AGEN or XOMA? Agenus presently has a consensus target price of $9.00, suggesting a potential upside of 145.90%. XOMA has a consensus target price of $69.50, suggesting a potential upside of 176.67%. Given XOMA's stronger consensus rating and higher possible upside, analysts clearly believe XOMA is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17XOMA 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in AGEN or XOMA? 61.5% of Agenus shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 5.5% of Agenus shares are held by insiders. Comparatively, 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation and earnings, AGEN or XOMA? XOMA has lower revenue, but higher earnings than Agenus. XOMA is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$99.52M1.01-$245.76M-$8.67-0.42XOMA$13.05M23.04-$40.83M-$1.15-21.84 Does the MarketBeat Community believe in AGEN or XOMA? Agenus received 26 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.52% of users gave Agenus an outperform vote while only 65.58% of users gave XOMA an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46868.52% Underperform Votes21531.48% XOMAOutperform Votes44265.58% Underperform Votes23234.42% Is AGEN or XOMA more profitable? Agenus has a net margin of -145.89% compared to XOMA's net margin of -151.34%. Agenus' return on equity of 0.00% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% XOMA -151.34%-24.95%-9.64% Which has more volatility & risk, AGEN or XOMA? Agenus has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. SummaryXOMA beats Agenus on 10 of the 18 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.28M$2.93B$5.37B$8.38BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.3330.5026.8419.71Price / Sales1.01400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book-0.473.286.794.50Net Income-$245.76M-$72.17M$3.23B$248.18M7 Day Performance5.48%4.28%4.07%1.14%1 Month Performance58.44%7.62%12.52%15.20%1 Year Performance-67.09%-28.15%16.83%6.56% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.968 of 5 stars$3.66-4.7%$9.00+145.9%-67.1%$105.28M$99.52M-0.33440Analyst RevisionGap DownXOMAXOMA4.0917 of 5 stars$24.79+2.5%$69.50+180.4%-3.0%$296.32M$10.22M-7.1210Insider TradeAnalyst RevisionGap UpLXRXLexicon Pharmaceuticals3.1961 of 5 stars$0.67-3.9%$3.67+444.1%-63.3%$243.61M$31.08M-0.90140VNDAVanda Pharmaceuticals4.3723 of 5 stars$4.03+2.0%$16.50+309.4%-15.5%$237.50M$198.77M-12.59290CDXSCodexis3.3106 of 5 stars$2.64+7.3%$8.00+203.0%-33.3%$218.71M$59.35M-3.03250Positive NewsAnalyst RevisionGap UpSGMOSangamo Therapeutics2.0489 of 5 stars$0.75+6.7%$5.17+591.8%-16.3%$171.16M$57.80M-1.00480Analyst ForecastAnalyst RevisionIRWDIronwood Pharmaceuticals4.528 of 5 stars$0.73+3.5%$4.78+551.9%-91.3%$118.74M$351.41M-24.46220Positive NewsACHVAchieve Life Sciences1.8853 of 5 stars$2.48+5.5%$14.33+478.0%-39.0%$86.02MN/A-2.1920Positive NewsGap UpDOMHDominari0.8663 of 5 stars$5.87-2.0%N/A+121.5%$85.96M$18.15M-1.524Positive NewsGap UpFBIOFortress Biotech1.6379 of 5 stars$1.65-2.4%$21.00+1,172.7%-14.1%$48.79M$57.68M-0.54170CRISCuris3.0391 of 5 stars$1.96+3.7%$21.00+971.4%-82.0%$20.51M$10.91M-0.2560Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies XOMA Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Codexis Alternatives Sangamo Therapeutics Alternatives Ironwood Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Dominari Alternatives Fortress Biotech Alternatives Curis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
